MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

29.79 0.81

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.58

Massimo

29.93

Metriche Chiave

By Trading Economics

Entrata

-16M

-97M

Vendite

361K

361K

EPS

-1.04

Margine di Profitto

-26,807.202

Dipendenti

437

EBITDA

-17M

-110M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+159.23% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-467M

2.7B

Apertura precedente

28.98

Chiusura precedente

29.79

Notizie sul Sentiment di mercato

By Acuity

50%

50%

115 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 lug 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 15:57 UTC

Discorsi di Mercato

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lug 2025, 15:49 UTC

Discorsi di Mercato

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Received All Required Authorizations

4 lug 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lug 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lug 2025, 14:30 UTC

Acquisizioni, Fusioni, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lug 2025, 13:53 UTC

Discorsi di Mercato

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 lug 2025, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 lug 2025, 12:30 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 lug 2025, 12:15 UTC

Discorsi di Mercato

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 lug 2025, 12:13 UTC

Discorsi di Mercato

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 lug 2025, 12:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

159.23% in crescita

Previsioni per 12 mesi

Media 77.25 USD  159.23%

Alto 97 USD

Basso 60 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

9

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

115 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.